Repligen Croissance future

Future contrôle des critères 4/6

Repligen devrait augmenter ses bénéfices et son chiffre d'affaires de 36.8% et de 14.7% par an respectivement. Le BPA devrait croître de de 35.4% par an. Le rendement des capitaux propres devrait être 8% dans 3 ans.

Informations clés

36.8%

Taux de croissance des bénéfices

35.38%

Taux de croissance du BPA

Life Sciences croissance des bénéfices	18.6%
Taux de croissance des recettes	14.7%
Rendement futur des capitaux propres	7.96%
Couverture par les analystes	Good
Dernière mise à jour	09 Sep 2026

Mises à jour récentes de la croissance future

Article d’analyse • Oct 31

Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Repligen Corporation ( NASDAQ:RGEN ) investors will be delighted, with the company turning in some strong numbers with...

Recent updates

Mise à jour du récit • Sep 04

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.

Seeking Alpha • May 31

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Summary Repligen is recovering after a difficult 2024, with Q1 2026 revenue up 15% and 11% organic. Polymem, China, PAT, and the Transformation Office make the story cleaner, but execution still matters. I like Repligen's balance sheet, as it has plenty of liquidity with good cash flows to continue funding M&A deals or potential growth in Asia. Unfortunately, my main issue with RGEN is its expensive valuation, which leaves little margin of safety for investors at these levels. Read the full article on Seeking Alpha

Mise à jour du récit • May 30

RGEN: Firmer Bioprocess Backdrop And Hubs Expansion Will Shape Long Term Outlook

Repligen's updated analyst price target of $142 reflects a largely unchanged fair value. Analysts point to a mix of reduced P/E assumptions and slightly stronger expectations for revenue growth and profitability, supported by recent research that highlights a firmer bioprocess backdrop and diversified growth drivers.

Mise à jour du récit • May 11

RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook

Analysts now place Repligen's fair value at $142, a $2 adjustment that reflects a mix of recent price target cuts and increases as they weigh updated growth expectations, margins, and P/E assumptions from the latest round of Street research. Analyst Commentary The latest Street research on Repligen shows a split tape, with some firms lifting targets and others cutting them, which nets out to the modest US$2 bump in the aggregated fair value estimate to US$142.

Mise à jour du récit • Apr 25

RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook

The analyst price target for Repligen has been reduced from about $160.90 to $140.00, as analysts factor in updated assumptions for revenue growth, profit margins, discount rates and future P/E following a mix of recent target cuts and one upward revision across the Street. Analyst Commentary Street research on Repligen over recent months points to a mixed but generally more cautious stance, with several firms trimming price targets while one research house lifted its target.

Mise à jour du récit • Apr 09

RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside

Narrative Update on Repligen The analyst price target for Repligen has been adjusted slightly lower, with the updated fair value moving from about $186.82 to $183.88 as analysts factor in recent target cuts, alongside generally positive views on guidance and execution. Analyst Commentary Recent Street research on Repligen clusters around a group of target cuts following the latest Q4 report and FY26 outlook, alongside a smaller number of target increases.

Mise à jour du récit • Mar 25

RGEN: Multi Year Guidance And M&A Focus Will Support Future Upside

Repligen's analyst price target has been adjusted modestly higher to $186.82, with analysts pointing to refreshed assumptions around revenue growth, profit margins, and future P/E expectations following recent target changes across firms such as H.C. Wainwright, UBS, Evercore ISI, Wells Fargo, and Barclays. Analyst Commentary Recent target changes reflect a mix of optimism and caution around Repligen, with analysts adjusting their models after the latest Q4 results and FY26 guidance.

Mise à jour du récit • Mar 10

RGEN: M&A And New Bioprocessing Resins Will Support Future Upside

Narrative Update: Repligen Repligen's updated analyst price target reflects a modest reset, with fair value moving from about $190.89 to $186.28 as analysts factor in slightly lower revenue growth and profit margin assumptions along with a marginally higher discount rate, while still generally highlighting solid recent execution and cautious company guidance. Analyst Commentary Recent Street research on Repligen shows a mixed but generally constructive stance, with several firms trimming price targets while maintaining positive ratings.

Mise à jour du récit • Feb 24

RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside

Analysts have raised their Repligen price target by $10 to $190.89, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$190.89 price target as better aligned with updated assumptions for discount rates and future P/E, suggesting the shares may not fully reflect their revised valuation framework.

Mise à jour du récit • Feb 09

RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook

Analysts have lifted their price target on Repligen by US$10, citing updated assumptions that reflect revised fair value estimates, a tweaked discount rate, adjusted revenue growth and profit margin expectations, and an updated future P/E multiple. Analyst Commentary Even with the higher price target, some research commentary points to risks that readers should keep in mind when weighing Repligen at current levels.

Mise à jour du récit • Jan 26

RGEN: Process Analytics Strength And Biopharma Recovery Will Support Further Upside

Analysts have nudged their price targets on Repligen higher, with our updated fair value estimate moving modestly to about US$190.89 per share. This is supported by recent Street research citing raised targets following a 3Q25 revenue beat and a relatively improving biopharma outlook, with growth across all franchises led by Process Analytics.

Mise à jour du récit • Jan 12

RGEN: Process Analytics Strength And Biopharma Recovery Will Support Upside In 2025

Analysts have lifted their price target on Repligen to about US$190 from US$187, pointing to recent target raises, including Canaccord's move to US$165 on 3Q25 revenue outperformance, a relatively improving biopharma outlook, and solid contributions from Process Analytics and other franchises. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a higher price target as a reflection of stronger than expected 3Q25 revenue, which they view as supportive of the current valuation range.

Mise à jour du récit • Dec 27

RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook

Narrative Update We are raising our Repligen fair value estimate from $131.29 to $160.36 per share as analysts lift price targets toward $160 to $165 on better than expected Q3 results, broad-based revenue growth led by Process Analytics, and an improving outlook for biopharma end markets. Analyst Commentary Recent Street research reflects a cautiously constructive stance on Repligen, with higher price targets acknowledging near term execution outperformance while still embedding meaningful risk around sustainability of growth.

Mise à jour du récit • Dec 13

RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential

Analysts have nudged our Repligen price target higher to $165, reflecting a modest trim to fair value estimates to about $216.62 per share, alongside slightly lower long term revenue growth and discount rate assumptions, but reinforced by recent target increases from the Street on better than expected quarterly results, improving biopharma demand, and confidence in the company s bioprocessing driven double digit growth potential. Analyst Commentary Bullish analysts have become incrementally more constructive on Repligen following its recent quarterly performance, citing a healthier biopharma demand backdrop and stronger than expected execution across key franchises.

Mise à jour du récit • Nov 27

RGEN: Volume Recovery and End-Market Stability Will Support Measured Upside in 2025

Narrative Update on Repligen Analysts have raised their price targets on Repligen by up to $15. They cite stronger-than-expected quarterly results and improved industry outlooks as driving positive momentum for the company.

Article d’analyse • Nov 12

Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point

Even though Repligen Corporation ( NASDAQ:RGEN ) posted strong earnings, investors appeared to be underwhelmed. We did...

Mise à jour du récit • Nov 11

RGEN: End-Market Improvements Will Drive Stronger Momentum Through 2025

Analysts have increased their price target for Repligen slightly, from $184.76 to $187.00. They cite a recent revenue beat, an improving sector outlook, and expectations for continued growth across key business areas.

Article d’analyse • Oct 31

Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Repligen Corporation ( NASDAQ:RGEN ) investors will be delighted, with the company turning in some strong numbers with...

Mise à jour du récit • Oct 28

Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum

Repligen's analyst price target has been increased from $179.78 to $184.76, as analysts see improving market stability and anticipate a return to stronger revenue growth despite recent headwinds. Analyst Commentary Recent updates from street research highlight a renewed sense of optimism among analysts, along with acknowledgment of ongoing industry challenges.

Article d’analyse • Oct 04

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Repligen Corporation ( NASDAQ:RGEN ) shares have had a really impressive month, gaining 28% after a shaky period...

Nouveau récit • May 26

Biomanufacturing Expansion Will Create New Global Opportunities

Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.

Seeking Alpha • Mar 20

Repligen: Ongoing Bioprocessing Market Recovery

Summary I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. Despite challenges in the protein business, I expect 12% organic revenue growth in FY25, supported by new product launches and market normalization. Read the full article on Seeking Alpha

Seeking Alpha • Nov 12

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Summary Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. Also, I believe international revenue exposure and foreign exchange volatility present additional risks for RGEN’s near-term financial performance. Despite a healthy underlying business, RGEN faces valuation concerns, tax loss harvesting, and uncertain growth, leading to a "Hold" rating ahead of its earnings report. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:RGEN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2028	1,145	141	199	266	13
12/31/2027	974	99	150	214	20
12/31/2026	827	42	121	166	22
6/30/2026	785	42	110	135	N/A
3/31/2026	763	51	104	131	N/A
12/31/2025	738	49	92	117	N/A
9/30/2025	708	2	103	131	N/A
6/30/2025	674	-14	103	132	N/A
3/31/2025	650	-23	117	146	N/A
12/31/2024	634	-26	142	175	N/A
9/30/2024	634	-8	131	165	N/A
6/30/2024	620	9	119	155	N/A
3/31/2024	620	24	110	147	N/A
12/31/2023	632	36	75	114	N/A
9/30/2023	653	101	97	147	N/A
6/30/2023	712	124	51	149	N/A
3/31/2023	761	154	46	160	N/A
12/31/2022	802	186	39	172	N/A
9/30/2022	801	166	15	160	N/A
6/30/2022	779	159	41	141	N/A
3/31/2022	734	146	42	133	N/A
12/31/2021	671	128	48	119	N/A
9/30/2021	593	119	35	84	N/A
6/30/2021	509	100	40	83	N/A
3/31/2021	433	80	32	62	N/A
12/31/2020	366	60	36	63	N/A
9/30/2020	327	44	44	65	N/A
6/30/2020	302	31	42	66	N/A
3/31/2020	286	23	N/A	67	N/A
12/31/2019	270	21	N/A	67	N/A
9/30/2019	253	23	N/A	55	N/A
6/30/2019	233	27	N/A	53	N/A
3/31/2019	210	21	N/A	41	N/A
12/31/2018	194	17	N/A	33	N/A
9/30/2018	184	23	N/A	42	N/A
6/30/2018	171	23	N/A	21	N/A
3/31/2018	155	29	N/A	18	N/A
12/31/2017	141	28	N/A	17	N/A
9/30/2017	125	21	N/A	4	N/A
6/30/2017	113	18	N/A	5	N/A
3/31/2017	110	13	N/A	12	N/A
12/31/2016	105	12	N/A	8	N/A
9/30/2016	100	7	N/A	9	N/A
6/30/2016	96	8	N/A	17	N/A
3/31/2016	88	8	N/A	14	N/A
12/31/2015	84	9	N/A	15	N/A
9/30/2015	78	9	N/A	13	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de RGEN ( 36.8% par an) est supérieure au taux d'épargne ( 3.7% ).

Bénéfices vs marché: Les bénéfices de RGEN ( 36.8% par an) devraient croître plus rapidement que le marché US ( 17.2% par an).

Croissance élevée des bénéfices: Les bénéfices de RGEN devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de RGEN ( 14.7% par an) devrait croître plus rapidement que le marché US ( 13.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de RGEN ( 14.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de RGEN devrait être faible dans 3 ans ( 8 %).

Découvrir les entreprises en croissance

Analyse de l'entreprise et données financières

Données	Dernière mise à jour (heure UTC)
Analyse de l'entreprise	2026/09/13 08:20
Cours de l'action en fin de journée	2026/09/11 00:00
Les revenus	2026/06/30
Revenus annuels	2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

Paquet	Données	Cadre temporel	Exemple de source américaine ^*
Finances de l'entreprise	10 ans	Compte de résultat Tableau des flux de trésorerie Bilan	Formulaire 10-K de la SEC Formulaire 10-Q de la SEC
Estimations consensuelles des analystes	+3 ans	Prévisions financières Objectifs de prix des analystes	Rapports de recherche des analystes Blue Matrix
Prix du marché	30 ans	Cours des actions Dividendes, scissions et actions	Données de marché ICE Formulaire S-1 de la SEC
Propriété	10 ans	Actionnaires principaux Délits d'initiés	Formulaire 4 de la SEC Formulaire 13D de la SEC
Gestion	10 ans	L'équipe dirigeante Conseil d'administration	Formulaire 10-K de la SEC Formulaire SEC DEF 14A
Principaux développements	10 ans	Annonces de l'entreprise	Formulaire 8-K de la SEC

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés^.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Repligen Corporation est couverte par 31 analystes. 22 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

Analyste	Institution
Luke Sergott	Barclays
Hugo Solvet	BNP Paribas
Paul Knight	Brean Capital Historical (Janney Montgomery)

Repligen Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 28%

Repligen Corporation Provides Earnings Guidance for the Full Year 2026

Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Repligen Corporation Updates Financial Guidance for the Full Year 2025

Repligen Corporation Updates Financial Guidance for the Full Year 2025

Repligen Corporation Reiterates Financial Guidance for the Year 2025

Recent updates

President notifies of intention to sell stock

RGEN: Cancer Vaccine Exposure And Bioprocess Deals Will Shape Outlook

President notifies of intention to sell stock

RGEN: Cancer Vaccine Hype And BioLife Deal Will Test Overstretched Expectations

Consensus EPS estimates fall by 28%

RGEN: Cell Therapy Deal And Gene Therapy Lap Will Drive Upside

New minor risk - Earnings quality

Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued

Repligen Corporation (NasdaqGS:RGEN) entered into an agreement and plan of merger to acquire BioLife Solutions, Inc. (NasdaqCM:BLFS) for approximately $1.6 billion.

Repligen to Acquire BioLife Solutions for $1.5 Billion to Expand Cell Therapy Offerings

Repligen Corporation to Report Q2, 2026 Results on Jul 28, 2026

Repligen Corporation(NasdaqGS:RGEN) dropped from Russell Midcap Growth Benchmark

RGEN: Bioprocess Recovery And Clean Gene Therapy Lap Will Drive Future Upside

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Now 21% undervalued

Repligen Has A Cleaner Recovery Angle, But With High Valuation

RGEN: Firmer Bioprocess Backdrop And Hubs Expansion Will Shape Long Term Outlook

Repligen Gains in Q1 But Weak Outlook Triggers Sharp Stock Decline

RGEN: Recalibrated Street Expectations And Hubs Expansion Will Shape Long Term Outlook

An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.

First quarter 2026 earnings: EPS misses analyst expectations

RGEN: recalibrated Street Expectations Will Shape Bullish Long Term Outlook

President notifies of intention to sell stock

Repligen Corporation to Report Q1, 2026 Results on May 05, 2026

Now 21% undervalued after recent price drop

RGEN: Multi Year Guidance And M&A Dry Powder Will Support Future Upside

Repligen Corporation, Annual General Meeting, May 14, 2026

RGEN: Multi Year Guidance And M&A Focus Will Support Future Upside

RGEN: M&A And New Bioprocessing Resins Will Support Future Upside

Now 22% undervalued after recent price drop

Full year 2025 earnings: EPS exceeds analyst expectations

Repligen Corporation Provides Earnings Guidance for the Full Year 2026

RGEN: M&A Focus And New Bioprocessing Resins Will Drive Future Upside

Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026

RGEN: M&A Ambitions And New Resins Portfolio Will Shape Bullish Outlook

RGEN: Process Analytics Strength And Biopharma Recovery Will Support Further Upside

RGEN: Process Analytics Strength And Biopharma Recovery Will Support Upside In 2025

Repligen Corporation Announces Executive Changes, Effective March 13, 2026

RGEN: Process Analytics Momentum And Biopharma Recovery Will Shape Risk Balanced Outlook

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

RGEN: Bioprocessing Recovery And Guidance Raise Will Support Upside Potential

President recently sold US$1.2m worth of stock

RGEN: Volume Recovery and End-Market Stability Will Support Measured Upside in 2025

President notifies of intention to sell stock

Executive Chair recently sold US$3.1m worth of stock

Executive Chair notifies of intention to sell stock

Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point

RGEN: End-Market Improvements Will Drive Stronger Momentum Through 2025

Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Repligen Corporation Updates Financial Guidance for the Full Year 2025

Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum

Now 23% undervalued

Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Executive Chair recently sold US$1.1m worth of stock

Executive Chair notifies of intention to sell stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Repligen Corporation Updates Financial Guidance for the Full Year 2025

Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025

Biomanufacturing Expansion Will Create New Global Opportunities

Repligen Corporation Reiterates Financial Guidance for the Year 2025

Repligen Corporation to Report Q1, 2025 Results on Apr 29, 2025

Repligen Corporation, Annual General Meeting, May 15, 2025

Repligen: Ongoing Bioprocessing Market Recovery

Repligen Corporation (NasdaqGS:RGEN) and Repligen GmbH acquired the assets related to bioprocessing analytics portfolio of 908 Devices Inc. (NasdaqGM:MASS) for $70 million.

Repligen Corporation announced delayed annual 10-K filing

Repligen Corporation Provides Earnings Guidance for the Year 2025